Onyx Biotec IPO

About  Onyx Biotec IPO

Onyx, founded in 2010, has become a prominent player in the pharmaceutical industry, particularly in the sterile water and injectable products sector. The company initially started its operations with sterile water for injections and has since expanded its portfolio to include a range of sterile pharmaceutical products. Onyx has established itself as a trusted supplier to top pharmaceutical companies across India, providing high-quality sterile products to meet the growing demand for critical care solutions. The company’s commitment to quality is reflected in its adherence to global standards, with its manufacturing processes certified under WHO-GMP and constant quality control measures in place.

With two state-of-the-art manufacturing facilities located in Himachal Pradesh, Onyx is well-equipped to meet the demands of both domestic and international markets. Unit I, which produces sterile water for injections, has a daily production capacity of 6,38,889 units, while Unit II manufactures dry powder injections and dry syrups, with daily capacities of 40,000 units and 26,667 units respectively. Onyx’s facilities are outfitted with modern equipment and adhere to sustainable practices, ensuring efficiency, product safety, and environmental responsibility. The company has undergone numerous audits and inspections by global regulators and clients, reinforcing its commitment to maintaining the highest standards of quality.

Onyx’s business model is centered on offering comprehensive product development and manufacturing solutions, as well as preparing regulatory dossiers for both domestic and international markets. The company’s robust quality assurance and quality control systems ensure that all products are tested and certified to meet stringent international standards. With a focus on continuous improvement, Onyx delivers consistent quality while also focusing on cost-efficiency and innovative solutions. This has earned the company repeat business from major clients such as Hetero Healthcare, Sun Pharmaceutical, Mankind Pharma, and many others, reinforcing its reputation as a reliable and trusted partner in the healthcare sector.

Looking ahead, Onyx is focused on expanding its capabilities with significant investments in its manufacturing infrastructure. The company plans to upgrade Unit I to manufacture large-volume parenteral products for intravenous use, which will cater to the growing critical care market. Additionally, Onyx will set up a high-speed packaging line at Unit II to enhance its efficiency in packaging dry powder injections. With a leadership team of experienced professionals and a commitment to providing cost-effective, high-quality products, Onyx is poised for continued growth and long-term success in the global pharmaceutical industry.

Onyx Biotec Limited prepares for its Initial Public Offering (IPO), the proceeds from the Fresh Issue will be allocated towards critical objectives

1. Upgradation of existing manufacturing Unit I to manufacture large volume parentals for intravenous use; 
2. Setting up a high-speed cartooning packaging line at existing manufacturing Unit II for Dry Powder Injections; 
3. Prepayment or repayment of all or a portion of certain loans availed by our Company; and 4. General Corporate Purposes.